We are committed to improving the lives of those who suffer from rare disorders. Our long track record of value creation and a mission-driven mindset has strong KOL support. Our R&D team has created 15+ businesses, advanced 12+ drugs into the clinic, and has been involved with 4 FDA and 3 EMA drug approvals in the last decade.
Our therapy in IND enabling studies for Epidermolysis bullosa and will be ready for the clinic mid-2024.
We are focused on first-in-class treatments for rare, genetic, and inflammatory disorders with multiple potential therapies orphan, breakthrough and pediatric designations.
Our founders have relevant experience in business creations, drug development and approvals; deep relationships with regulators and unique patient perspective.
Our historical track record is of value creation with a mission-driven mindset, deep peer support and joint vision of creating a market leader. Our culture, based on sense purpose balanced with sustainable & profitable solutions to attract future talent and sustain our efforts and successes, guides our path as we work to make life more normal for those who are affected by rare disorders. Phoenicis has the vision, team, and product breadth & depth to enable success and significant shareholder value creation.
Our therapy, human recombinant decorin, is in IND enabling studies for Dystrophic epidermolysis bullosa, will be ready for the clinic mid-2024. There is potential pipeline-in-a-product opportunity with therapeutic potential in multiple inflammatory and fibrotic indications, including hydrocephalus, glaucoma and idiopathic pulmonary fibrosis.
PTD-003: Topical decorin is a major natural physiological switch that prevents and reverses fibrosis
Compelling, published pre-clinical data from multiple independent labs demonstrating the therapeutic potential of recombinant decorin (hrDecorin)
No adequate treatments for fibrotic diseases of the skin, e.g., keloids, hypertrophic scars, scarring due to epidermolysis bullosa (EB)
Low manufacturing risk
Completed IND-enabling toxicology studies
Phase 1/2 clinical study in DEB planned for mid-2024
Potential pipeline-in-a-product opportunity: potential to expand to other fibrotic diseases such as hydrocephalus, idiopathic pulmonary fibrosis, myopia, and glaucoma
